Skip to content

A Pivotal Study to Evaluate Enlite™ Sensor Performance With iPro™2 in China

A Pivotal Study to Evaluate Enlite™ Sensor Performance With iPro™2 in China

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03417466
Enrollment
72
Registered
2018-01-31
Start date
2018-06-28
Completion date
2018-09-20
Last updated
2019-08-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes Mellitus

Keywords

Diabetes Type I Type II

Brief summary

The purpose of this study is to demonstrate the performance and safety of the Enlite Sensor over 144 hours (6 days) when inserted in the abdomen and used with the iPro2 in subjects age 14 - 75 years.

Detailed description

This study is a multi-center, randomized, prospective single-sample correlational design without controls. Up to 72 subjects will be enrolled in order to have approximately 60 subjects complete the study. Three investigational centers in China will be used during this study. Each subject will wear the following devices: • Two Enlite Sensors each connected to an iPro2 for approximately 6 days Sensor Location: • The 2 Enlite Sensors will be worn in the abdomen area. Investigational center staff will insert sensors and connect to the iPro2s. During the study, each subject will be randomized and undergo one Yellow Springs Instrument (YSI™) frequent sample testing (FST) (Day 1, 3-4, or 6). During the study, subjects will continue with their current diabetes regimen independent of the study devices. Subjects will be instructed by the investigational center that they are not to use the study devices (except for the study meter) for the management of their diabetes. The Study Meter may be used for treatment decisions and calibration of Enlite Sensor.

Interventions

DEVICEEnlite 1 connected to iPro2 recorder

Use Enlite Sensor over 144 hours (6 days) when inserted in the abdomen and used with the iPro2 in subjects age 14 - 75 years.

Sponsors

Medtronic Diabetes
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
14 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

1. Subject is 14 - 75 years of age at time of screening 2. Subject has a clinical diagnosis of type 1 or 2 diabetes as determined via medical record or source documentation by an individual qualified to make a medical diagnosis 3. Subject has adequate venous access as assessed by investigator or appropriate staff 4. Subject is willing to follow the study procedures and willing to come to study visits. 5. Subject is willing to perform at least 4 self-monitoring of blood glucose (SMBG) per day for 6 days

Exclusion criteria

1. Subject will not tolerate tape adhesive in the area of Enlite Sensor placement as assessed by qualified individual. 2. Subject has any unresolved adverse skin condition in the area of study device or device placement (e.g., psoriasis, rash, Staphylococcus infection) 3. Subject is actively participating in an investigational study (drug or device) wherein they have received treatment from an investigational study (drug or device) in the last 2 weeks 4. Subject is female and has a positive pregnancy screening test 5. Females of child bearing age and who are sexually active should be excluded if they are not using a form of contraception deemed reliable by investigator 6. Subject is female and plans to become pregnant during the course of the study 7. Subject has a hematocrit (Hct) lower than the normal reference range 8. Subject may not be on the research staff of those performing this study

Design outcomes

Primary

MeasureTime frameDescription
Mean Percentage of Enlite Sensor Values That Are Within 20% Agreement of Gold Standard (Yellow Springs Instrument (YSI) YSI Plasma Glucose Values)YSI FST days (Day 1, 3-4, or 6 of sensor wear)Primary endpoint is the mean percentage of Enlite Sensor Values from primary sensor that are within 20% agreement of YSI plasma glucose values (within 20 mg/dL if YSI \<= 80 mg/dL) during YSI frequent sampling testing (FST) days.

Secondary

MeasureTime frameDescription
Enlite Sensor Accuracy Mean Absolute Relative Difference (MARD)YSI FST days (Day 1, 3-4, or 6 of sensor wear)Enlite sensor values from primary sensor were compared to YSI plasma glucose values during YSI FST days (Day 1, 3-4, or 6). MARD = Mean of ((Absolute difference of YSI reference and Sensor glucose values / YSI reference glucose values) \* 100). Therefore, the unit of MARD is percentage (%).
Clarke Error Grid Analysis of Paired Sensor and YSI Plasma Glucose ValuesYSI FST days (Day 1, 3-4, or 6 of sensor wear)Clarke Error Grid compared the paired primary sensor and YSI reference glucose values. Zone A represents a region where sensor values that are within 20% of YSI reference values, or both sensor and YSI reference values are less than 70 mg/dL. Values in Zone A are clinically accurate in that they would lead to clinically correct treatment decisions. Zone B represents sensor values that deviate YSI reference values by more than 20%, but would lead to benign or no treatment. Ideal situation is 100% in Zone A + B.
Consensus Error Grid Analysis of Paired Sensor and YSI Plasma Glucose ValuesYSI FST days (Day 1, 3-4, or 6 of sensor wear)Consensus Error Grid (or Parkes error grid) compared the paired primary sensor and YSI reference glucose values. Zone A is defined in the Parkes error grid as the zone of clinical accurate measurements with no effect on clinical action, Zone B as altered clinical action with little or no effect on clinical outcome. Ideal situation is 100% in Zone A + B.

Countries

China

Participant flow

Pre-assignment details

A total of 72 subjects signed the informed consent form and completed the screening. Five subjects failed the screening. One subject withdrew before wearing the sensor.

Participants by arm

ArmCount
Study Arm
Use Enlite Sensor over 144 hours (6 days) when inserted in the abdomen and used with the iPro2 and undergo one Yellow Springs Instrument (YSI™) frequent sample testing (FST) (Day 1, 3-4, or 6)
66
Total66

Baseline characteristics

CharacteristicStudy Arm
Age, Continuous52.82 years
STANDARD_DEVIATION 12.56
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
Race (NIH/OMB)
Asian
66 Participants
Race (NIH/OMB)
Black or African American
0 Participants
Race (NIH/OMB)
More than one race
0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants
Race (NIH/OMB)
White
0 Participants
Region of Enrollment
China
66 participants
Sex: Female, Male
Female
32 Participants
Sex: Female, Male
Male
34 Participants

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
0 / 66
other
Total, other adverse events
5 / 66
serious
Total, serious adverse events
0 / 66

Outcome results

Primary

Mean Percentage of Enlite Sensor Values That Are Within 20% Agreement of Gold Standard (Yellow Springs Instrument (YSI) YSI Plasma Glucose Values)

Primary endpoint is the mean percentage of Enlite Sensor Values from primary sensor that are within 20% agreement of YSI plasma glucose values (within 20 mg/dL if YSI \<= 80 mg/dL) during YSI frequent sampling testing (FST) days.

Time frame: YSI FST days (Day 1, 3-4, or 6 of sensor wear)

Population: Subjects who have Enlite sensor inserted and have at least one paired Enlite sensor and YSI measurement. 66 subjects have Enlite sensor inserted, of which one subject has no paired Enlite sensor and YSI measurement.

ArmMeasureValue (MEAN)Dispersion
Study ArmMean Percentage of Enlite Sensor Values That Are Within 20% Agreement of Gold Standard (Yellow Springs Instrument (YSI) YSI Plasma Glucose Values)85.74 percentage of paired readingsStandard Deviation 22.26
Secondary

Clarke Error Grid Analysis of Paired Sensor and YSI Plasma Glucose Values

Clarke Error Grid compared the paired primary sensor and YSI reference glucose values. Zone A represents a region where sensor values that are within 20% of YSI reference values, or both sensor and YSI reference values are less than 70 mg/dL. Values in Zone A are clinically accurate in that they would lead to clinically correct treatment decisions. Zone B represents sensor values that deviate YSI reference values by more than 20%, but would lead to benign or no treatment. Ideal situation is 100% in Zone A + B.

Time frame: YSI FST days (Day 1, 3-4, or 6 of sensor wear)

Population: Subjects who have Enlite sensor inserted and have at least one paired Enlite sensor and YSI measurement. 66 subjects have Enlite sensor inserted, of which one subject has no paired Enlite sensor and YSI measurement.

ArmMeasureValue (MEAN)
Study ArmClarke Error Grid Analysis of Paired Sensor and YSI Plasma Glucose Values98.4 percentage of paired readings
Secondary

Consensus Error Grid Analysis of Paired Sensor and YSI Plasma Glucose Values

Consensus Error Grid (or Parkes error grid) compared the paired primary sensor and YSI reference glucose values. Zone A is defined in the Parkes error grid as the zone of clinical accurate measurements with no effect on clinical action, Zone B as altered clinical action with little or no effect on clinical outcome. Ideal situation is 100% in Zone A + B.

Time frame: YSI FST days (Day 1, 3-4, or 6 of sensor wear)

Population: Subjects who have Enlite sensor inserted and have at least one paired Enlite sensor and YSI measurement. 66 subjects have Enlite sensor inserted, of which one subject has no paired Enlite sensor and YSI measurement.

ArmMeasureValue (MEAN)
Study ArmConsensus Error Grid Analysis of Paired Sensor and YSI Plasma Glucose Values99.4 percentage of paired readings
Secondary

Enlite Sensor Accuracy Mean Absolute Relative Difference (MARD)

Enlite sensor values from primary sensor were compared to YSI plasma glucose values during YSI FST days (Day 1, 3-4, or 6). MARD = Mean of ((Absolute difference of YSI reference and Sensor glucose values / YSI reference glucose values) \* 100). Therefore, the unit of MARD is percentage (%).

Time frame: YSI FST days (Day 1, 3-4, or 6 of sensor wear)

Population: Subjects who have Enlite sensor inserted and have at least one paired Enlite sensor and YSI measurement. 66 subjects have Enlite sensor inserted, of which one subject has no paired Enlite sensor and YSI measurement.

ArmMeasureValue (MEAN)Dispersion
Study ArmEnlite Sensor Accuracy Mean Absolute Relative Difference (MARD)10.11 percentage of differenceStandard Deviation 8.16

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026